A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab Into a First-in-Human Clinical Trial.

Clin Pharmacol Ther · 2022 · PMC8653169 · PMID 34687040

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Given the enormous financial and logistical costs associated with producing and distributing drugs to such a vast patient population, the implications of this drastically reduced efficacious dose from a public health perspective are highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.